MEA Animal Parasiticides Market

MEA Animal Parasiticides Market Size (2022 to 2027)

The size of the Middle East & Africa Animal Parasiticides Market was worth USD 0.84 Billion in 2022. It is expected to grow at a CAGR of 5.55% and value USD 1.11 Billion by 2027.

The market shows significant growth potential in the aforementioned period. It will continue to gain momentum in future years with the gradual increase in awareness about animal health.

Animal parasiticides are special medicines to treat animals that are infected by parasites. They are generally inert substances that are mixed together. Most ingredients of a parasiticide have the same kind of chemical structures and share many features. Many times, they are classified according to the chemical families. Animal parasiticides are considered very important for the protection of animals from parasitic diseases.

An increasing amount of capital spent on the healthcare of animals as well as the growing trend of adopting pet animals is the drivers for the growth of the Middle-East and Africa Animal Parasiticides market. Also, increasing awareness about meat quality and other animal products has led to a lot of development in the animal healthcare sector. However, a rise in the population of vegetarians and vegans as well as strict restrictions imposed on the approval of these medicines are the major challenges faced by Middle-East and Africa animal parasiticides market.

This research report on the MEA Animal Parasiticides Market has been segmented and sub-segmented into the following categories:

By Product:

• Ectoparasiticides
• Endoparasiticides

By Animal type:

• Food-producing Animals (Cattle, Sheep and Goats, Pigs, Poultry, and others)
• Companion Animals (Dogs, Cats, Horses, and others)

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Companies operating in the MEA animal parasiticides market profiled in the report are Sanofi S.A. (Merial), Ceva Sante Animale, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc.